Currently, there are 32.67M common shares owned by the public and among those 32.23M shares have been available to trade.
The company’s stock has a 5-day price change of -28.01% and -37.79% over the past three months. TMDX shares are trading 12.12% year to date (YTD), with the 12-month market performance up to 133.08% higher. It has a 12-month low price of $36.42 and touched a high of $177.37 over the same period. TMDX has an average intraday trading volume of 1.13 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -31.52%, -39.38%, and -27.64% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Transmedics Group Inc (NASDAQ: TMDX) shares accounts for 103.16% of the company’s 32.67M shares outstanding.
It has a market capitalization of $2.95B and a beta (3y monthly) value of 2.01. The stock’s trailing 12-month PE ratio is 94.63, while the earnings-per-share (ttm) stands at $0.94. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.73% over the week and 4.70% over the month.
Earnings per share for the fiscal year are expected to increase by 236.47%, and 57.04% over the next financial year.
Looking at the support for the TMDX, a number of firms have released research notes about the stock. Oppenheimer stated their Outperform rating for the stock in a research note on Oct-30-24, with the firm’s price target at $200-$125. Needham coverage for the Transmedics Group Inc (TMDX) stock in a research note released on October 30, 2024 offered a Buy rating with a price target of $109. Robert W. Baird was of a view on September 24, 2024 that the stock is Outperform, while Needham gave the stock Buy rating on August 21, 2024, issuing a price target of $208. Cantor Fitzgerald on their part issued Overweight rating on June 06, 2024.
